FDA Inspection 1140901 — Incyte Corporation

Incyte Corporation — FEI 3008992769

The FDA completed an inspection of Incyte Corporation on April 16, 2021 in Wilmington, DE. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 16, 2021
Fiscal Year
2021
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Wilmington, DE (United States)

Additional Details

Sponsor, Contract Research Organization